Proteomic detection of nitroproteins as potential biomarkers for cardiovascular disease

Aslan, Mutay; Doğan, Serdar

doi:10.1016/j.jprot.2011.05.029

Cited by 17 publications

(16 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular disease (CVD) refers to any disorder which disturbs the cardiovascular system, and so forth [1]. The World Health Organization (WHO) has revealed that CVD has become the leading cause of mortality worldwide; more individuals die from CVD than from any other disorders each year (http://www.who.int/mediacentre/factsheets/fs317/en/).…”

Section: Introductionmentioning

confidence: 99%

“…The World Health Organization (WHO) has revealed that CVD has become the leading cause of mortality worldwide; more individuals die from CVD than from any other disorders each year (http://www.who.int/mediacentre/factsheets/fs317/en/). CVD's estimated mortality rate is 17.1 million per year, representing 29 percent of the overall deaths worldwide, and its total mortality possibly exceeds one hundred million [1, 2]. Moreover, according to American Heart Association Statistics Committee and Stroke Statistics Subcommittee, though its death rate has fallen since the 1970s, CVD remains the leading cause of mortality in developed countries [3].…”

Section: Introductionmentioning

confidence: 99%

“…Being an age-specific disorder, there is abundance of evidence to suggest that there are multiple risk factors for CVD, including tobacco smoking, air pollution from the solid fuels, hyperlipidemia, diabetes, consumption of alcohol and sugar, obesity, and family history [4–6]. Additionally, varying serum levels of several proteins such as nitroproteins and the C-reactive protein have been reported to be related to CVD, and the fetuin-A (FA) protein has recently been the target of an increasing number of investigated cardiovascular disease [1, 7, 8]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum Fetuin-A Levels in Patients with Cardiovascular Disease: A Meta-Analysis

Sun

Xie

Guo

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Background. Fetuin-A (FA) suppresses arterial calcification, promotes insulin resistance, and appears to be elevated in patients with cardiovascular diseases (CVD), but the data is still inconsistent. To clarify the correlation between serum FA levels and the presence and severity of CVDs, we performed this meta-analysis. Method. Potential relevant studies were identified covering the following databases: PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, China BioMedicine (CBM), and China National Knowledge Infrastructure (CNKI) databases. Data from eligible studies were extracted and included in the meta-analysis using a random-effects model. Results. Ten case-control studies, including 1,281 patients with CVDs and 2,663 healthy controls, were included. The results showed significant differences in serum levels of FA between the CVDs patients and the healthy controls (SMD = 1.36, 95%CI: 0.37–2.36, P = 0.007). Ethnicity-subgroup analysis implied that low serum FA levels are related to CVDs in Caucasians (SMD = 1.73, 95%CI: 0.20–3.26, P = 0.026), but not in Asians (SMD = 1.04, 95%CI: −0.33–2.40, P = 0.138). Conclusion. The data indicated that decreased serum FA level is correlated with the development of CVDs. FA might be clinically valuable for reflecting the progression of CVDs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Fetuin-A Levels in Patients with Cardiovascular Disease: A Meta-Analysis

Sun

Xie

Guo

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In the United States, it has been estimated that 83 million people have CCVDs -nearly one in three adults -, which accounts for 20% of all medical expenditure, equaling 298 billion dollars and leading to an excessive hospital admission and medical health burden (Montgomery and Brown, 2013). However, low-and middle-income countries may account for approximately 82% of mortalities due to CCVDs globally (Aslan and Dogan, 2011). Owing to the serious implications of CCVDs, more effective prognostic prediction by objectively measuring left atrial size and volume has been introduced, with the aim of preventing the progression of CCVDs (Russo et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. Cardiovascular and cerebrovascular diseases (CCVDs) are common and have high rates of morbidity, mortality, and recurrence. Thrombin-activatable fibrinolysis inhibitor (TAFI) is also known as carboxypeptidase B2 and is encoded by the CPB2 gene; CPB2 polymorphisms have been explored in a variety of studies, but their correlation to the risk of CCVDs remains ambiguous. We examined the hypothesized associations between CPB2 mutations and CCVDs in a general population. We searched, Embase, the Cumulative Index to Nursing and Allied Health Literature, the Science Citation Index, and several Chinese databases without applying any language restrictions. Nine case-control studies were analyzed in the current meta-analysis, and odds ratios (ORs) with their 95% confidence intervals were calculated. The pooled ORs indicated that the CPB2 rs3742264 G>A polymorphism was associated with an increased risk of CCVDs in the allele model (all P values < 0.05). A similar result for the CPB2 rs1926447 C>T polymorphism and CCVDs risk was detected in the allele model (P < 0.05). Ethnicity subgroup analysis implied that the rs3742264 G>A polymorphism was more likely to lead to the development of cerebrovascular disease in Asians (all P values < 0.05), whereas rs1926447 C>T was associated with cardiovascular disease among Africans (all P values < 0.05). These data suggest that the polymorphisms investigated, especially rs3742264 G>A and rs1926447 C>T, have a modest effect on susceptibility to CCVDs.

show abstract

“…The method has been applied in a qualitative “shotgun” design using data-dependent LC–MS/MS for the identification of protein targets of posttranslational Tyr nitration including precise identification of the modification sites 21 . With their improved detection sensitivity and increased speed of acquisition, newer mass spectrometers should permit applications to not only test-tube or cell-culture experiments but also to tissue-derived samples in studies focused on this important PTM as a signaling event 3,31 or as a biomarker of nitroxidative stress 2,32 affecting a specific subset of proteins in the proteome and, also, localized to specific Tyr residues within these targeted proteins.…”

Section: Introductionmentioning

confidence: 99%

Selective chemoprecipitation to enrich nitropeptides from complex proteomes for mass-spectrometric analysis

2014

View full text Add to dashboard Cite

Posttranslational protein nitration has attracted interest due to its involvement in cellular signaling, effects on protein function, and as a potential biomarker of nitroxidative stress. We describe a procedure for enriching nitropeptides for mass spectrometry-based proteomics that is a simple and reliable alternative to immunoaffinity-based methods. The starting material for this procedure is a proteolytic digest. The peptides are reacted with formaldehyde and sodium cyanoborohydride to dimethylate all the N-terminal and side-chain amino groups. Sodium dithionite is added subsequently to reduce the nitro groups to amines; in theory, the only amino groups present will have originally been nitro groups. The peptide sample is then applied to a solid-phase active ester reagent, and those peptides with amino groups will be selectively and covalently captured. Release of the peptides on hydrolysis with trifluoroacetic acid results in peptides that have a 4-formyl-benzamido group where the nitro group used to be. In qualitative setups, the procedure can be used to identify proteins modified by reactive nitrogen species and to determine the specific sites of their nitration. Quantitative measurements can be performed by stable-isotope labeling of the peptides in the reductive dimethylation step. Preparation of the solid-phase active ester reagent takes about 1 day. Enrichment of nitropeptides requires about 2 days, and sample preparations need 1 to 30 h varying based on experimental design. LC–MS/MS assays take from 4 h to several days and data processing can be done 1 to 7 days.

show abstract

Proteomic detection of nitroproteins as potential biomarkers for cardiovascular disease

Cited by 17 publications

References 119 publications

Serum Fetuin-A Levels in Patients with Cardiovascular Disease: A Meta-Analysis

Serum Fetuin-A Levels in Patients with Cardiovascular Disease: A Meta-Analysis

Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases

Selective chemoprecipitation to enrich nitropeptides from complex proteomes for mass-spectrometric analysis

Contact Info

Product

Resources

About